Adrenocortical cancer treatment

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 99-104

  Patalano, A ^a   Brancato, V ^a   Mantero, F ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adrenocortical cancer; FIRM ACT; Mitotane

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; HYDROCORTISONE; IODOCHOLESTEROL; MINERALOCORTICOID; MITOTANE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN B; STREPTOZOCIN; TUMOR PROTEIN; VASCULOTROPIN;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADULT; AGE DISTRIBUTION; ANOREXIA; ATAXIA; BECKWITH WIEDEMANN SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURGERY; CARNEY COMPLEX; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG BLOOD LEVEL; FAMILIAL CANCER; FLUSHING; GYNECOMASTIA; HISTOLOGY; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IMPOTENCE; LETHARGY; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; MUSCLE WEAKNESS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; SCINTIGRAPHY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ATROPHY; SOMATIC MUTATION; SOMNOLENCE; STEROIDOGENESIS; THROMBOCYTE AGGREGATION;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOTANE; PROGNOSIS; STREPTOZOCIN; SYNDROME;

EID: 58549084169     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178049     Document Type: Conference Paper

References (29)

1. Mantero F, Terzolo M, Araldi G, Osella G, Masini AM, Alì A, Giovanetti M, Opocher G, Angeli A: A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637-644.
2. Allolio B, Hahner S, Weismann D, Fassnacht M: Management of adrenocortical carcinoma. Clin Endocrinol 2004;60:273-287.
3. Reincke M, Beuschlein F, Slawik M, Borm K: Molecular adrenocortical tumorigenesis. Eur J Clin Invest 2000;30:63-68.
4. Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28.
5. Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palu G, Boscaro M: Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 2001;145:207-212.
6. Libè R, Bertherat J: Molecular genetics of adrenocortical tumors, from familial to sporadic diseases. Eur J Endocrinol 2005;153:477-487.
7. De Frapoint F, Atifi El, Gicquel C, Bertagna X, Chambaz EM, Feige J: Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab 2000;85:4734-4741.
8. Arlt W, Hahner S, Libe R, Hughes BA, Shackleton CHL, Opocher G, Quinkler M, Bertherat J, Allolio B, Mannelli M, Mantero F, Fassnacht M, Bertagna X, Stewart PM: Steroid profiling in the diagnosis and monitoring of adrenocortical cancer - results of the EURINE ACC Study of the European Network for the Study of Adrenal Tumors (ENS@T). Program & AbstractBook, 90th Annual Meeting, San Francisco, 2008, p 146.
9. Gicquel C, Bertherat J, Le Bouc Y, Bertagna X: Pathogenesis of adrenocortical incidentalomas and genetic syndromes associated with adrenocortical neoplasm. Endocrinol Metab Clin N Am 2000;29:1-13.
10. Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, Ali A, Pascotti P, Porpiglia F, Fontana D, Angeli A: Immunohistochemical assessment of Ki67 in the differential diagnosis of adrenocortical tumors. Urology 2001;57:176-182.
11. Tessier F, Louvel A, Grabar S, Hagnere AM, Bertherat J, Vacher-Lavenu MC, Dousset B, Chapuis Y, Bertagna X, Gicquel C: Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 2004;150:809-817.
12. Terzolo M, Ali A, Osella G, Mazza E: Prevalence of adrenal carcinoma among incidentally discovered adrenal messes. A retrospective study from 1989 to 1994. Arch Surg 1997;132:914-919.
13. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg 2005;71:90-94.
14. Kreissing R, Amthauer H, Krude H, Steinmueller P, Stroszczynski C, Hosten N, Grueters A, Felix R: The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol 2000;30:306.
15. Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M: Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006;91:920-925.
16. Weiss LM: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-169.
17. Weiss LM, Medeiros LJ, Vickery AL Jr: Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-206.
18. Pohlink C, Tannapfe A, Eichfeld U, Schmidt F, Fuhrer D, Paschke R, Koch CA: Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors? J Endocrinol Invest 2004;27:565-569.
19. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP: Management of patients with adrenal cancer: recommendations of an International Consensus Conference. Endocr Relat Cancer 2005;12:667-680.
20. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J: Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-2655.
21. Cobb W, Kercher K, Sing R, Heniford B: Laparoscopic adrenalectomy for malignancy. Am J Surg 2005;189:405-411.
22. Wood BJ, Abrahman J, Hvizda JL, Alexander HR, Fojo T: Radiofrequency ablation of adrenal tumors in adrenocortical carcinoma metastases. Cancer 2003;97:554-560.
23. Allolio B, Fassnacht M: Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-2037.
24. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, et al: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-1210.
25. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-2380.
26. Bertherat J, Coste J, Bertagna X: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 2007;357:1256-1257.
27. Skogseid B, Baudin E, Fassnacht M, Haak H, Terzolo M: Experience from an ongoing phase III study: FIRM-ACT. Abstract Book of the 2nd Annual International Adrenal Cancer Symposium: Clinical and Basic Science, 2008.
28. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-666.
29. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson B: Streptozotocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-1287.